GO:0008120 ceramide glucosyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008120 ceramide glucosyltransferase activity catalyzes the transfer of glucose from UDP-glucose to ceramide, forming glucosylceramide, the committed step in glycosphingolipid biosynthesis.
• The enzyme is encoded by UGCG (UDP-glucose ceramide glucosyltransferase) and is localized to the Golgi apparatus.
• UGCG activity is essential for CD8+ T cell function and tumor control, linking glycosphingolipid biosynthesis to immune surveillance.
• Inhibitors such as WP1066 and eliglustat target UGCG or its pathway, with clinical relevance in cancer and Gaucher disease.
• UGCG upregulation is associated with venous malformations and acute myeloid leukemia (AML) resistance to venetoclax.
• Research methods include activity assays with deuterated glucosylceramide, CRISPR knockout, and lipidomics.
Description
Ceramide glucosyltransferase activity (GO:0008120) is a molecular function that catalyzes the transfer of glucose from UDP-glucose to ceramide, producing glucosylceramide and UDP. This reaction is the first and rate-limiting step in the synthesis of glycosphingolipids, a diverse class of lipids that play critical roles in cell signaling, membrane structure, and immune recognition. The enzyme responsible, UGCG (also known as glucosylceramide synthase), is a Golgi-resident protein that is highly conserved across eukaryotes. Dysregulation of UGCG activity has been implicated in a range of pathologies, including cancer, venous malformations, and skin disorders. Understanding the regulation and function of this enzyme is therefore of broad interest to researchers in cell biology, immunology, and oncology. This article provides a comprehensive overview of GO:0008120, covering its definition, mechanism, key genes, disease associations, and experimental approaches for studying it.
ceramide glucosyltransferase activity At A Glance
| GO ID | GO:0008120 |
|---|---|
| GO term | ceramide glucosyltransferase activity |
| Ontology | molecular_function |
| Synonym | glucosylceramide synthase activity; UDP-glucose:ceramide glucosyltransferase activity; ceramide:UDP-glucose glucosyltransferase activity |
| Major function | Catalyzes the transfer of glucose from UDP-glucose to ceramide, forming glucosylceramide and UDP |
| Reaction | an N-acylsphing-4-enine + UDP-alpha-D-glucose = a beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine + H+ + UDP |
| Enzyme | UGCG (UDP-glucose ceramide glucosyltransferase) |
| Localization | Golgi apparatus membrane |
| Pathway | Glycosphingolipid biosynthesis - glucosylceramide series |
What Is GO:0008120?
According to the Gene Ontology, GO:0008120 ceramide glucosyltransferase activity is defined as the catalysis of the reaction: an N-acylsphing-4-enine (ceramide) + UDP-alpha-D-glucose = a beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine (glucosylceramide) + H+ + UDP. In simpler terms, it is the enzyme activity that attaches a glucose molecule to ceramide, creating glucosylceramide, a key building block for more complex glycosphingolipids.
Why Is ceramide glucosyltransferase activity Important in Cell Biology?
Ceramide glucosyltransferase activity is a critical node in sphingolipid metabolism because it diverts ceramide, a pro-apoptotic lipid, toward the synthesis of glycosphingolipids, which promote cell survival, proliferation, and signaling. This balance is crucial in cancer, where elevated UGCG activity can confer resistance to chemotherapy and targeted therapies. Moreover, glucosylceramide and its derivatives are essential for immune cell function, as shown by the requirement for glucose-dependent glycosphingolipid biosynthesis in CD8+ T cell-mediated tumor control. The enzyme is also a therapeutic target: inhibitors like eliglustat are used in Gaucher disease, and UGCG inhibition sensitizes AML cells to venetoclax. Thus, understanding GO:0008120 has direct implications for drug development and disease intervention.
• UGCG activity is the rate-limiting step in glycosphingolipid biosynthesis, influencing membrane composition and signaling.
• It supports CD8+ T cell function and tumor control by fueling glycosphingolipid biosynthesis.
• Inhibition of UGCG activity by WP1066 reduces ceramide glucosylation, affecting JAK/STAT3 signaling.
• UGCG upregulation is observed in venous malformations, contributing to aberrant vascular development.
• In AML, targeting UGCG sensitizes cells to venetoclax through RAB32-mediated ER-mitochondria communication.
• Eliglustat, a UGCG inhibitor, is approved for Gaucher disease type 1, demonstrating clinical utility.
• Aryl hydrocarbon receptor activation upregulates UGCG in epidermal keratinocytes, linking environmental factors to skin barrier function.
• Ceramide glucosyltransferase activity is induced during keratinocyte differentiation, highlighting its role in skin biology.
• Sensitive activity assays using deuterated glucosylceramide enable precise measurement in biological samples.
• UGCG is a potential therapeutic target across cancers, metabolic disorders, and inflammatory diseases.
What Happens During ceramide glucosyltransferase activity?
Substrate Recognition and Binding
In simple terms: The enzyme grabs ceramide and UDP-glucose, the two starting materials.
UGCG binds its substrates, ceramide and UDP-glucose, in the Golgi membrane. The enzyme recognizes the N-acylsphing-4-enine (ceramide) and UDP-alpha-D-glucose, positioning them for catalysis. This step is essential for the subsequent transfer reaction.
Catalytic Transfer of Glucose
In simple terms: The enzyme moves glucose from UDP-glucose onto ceramide, creating glucosylceramide.
The catalytic mechanism involves the transfer of glucose from UDP-glucose to the primary hydroxyl group of ceramide, forming beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine (glucosylceramide) and releasing UDP and H+. This reaction is the committed step in glycosphingolipid synthesis.
Product Release and Membrane Dynamics
In simple terms: The newly made glucosylceramide is released into the membrane for further processing.
After catalysis, glucosylceramide is released into the Golgi membrane, where it can be further glycosylated to form more complex glycosphingolipids. The enzyme also releases UDP and H+. Proper product release is critical for maintaining lipid homeostasis.
Regulation by Cellular Signals
In simple terms: The enzyme's activity can be turned up or down by signals inside the cell.
UGCG activity is regulated by various factors, including the aryl hydrocarbon receptor (AhR) pathway, which upregulates UGCG expression in keratinocytes. Additionally, the JAK/STAT3 pathway inhibitor WP1066 directly inhibits ceramide glucosyltransferase activity. These regulatory mechanisms ensure appropriate glycosphingolipid levels.
Key Genes Involved in GO:0008120 ceramide glucosyltransferase activity
The following genes and proteins are directly involved in ceramide glucosyltransferase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| UGCG | Encodes ceramide glucosyltransferase, the enzyme catalyzing GO:0008120 | Knockout reduces glucosylceramide; target in cancer and Gaucher disease |
| GBA | Glucocerebrosidase, degrades glucosylceramide | Mutations cause Gaucher disease; interplay with UGCG |
| CYP2D6 | Cytochrome P450 enzyme metabolizing eliglustat | Genotype affects eliglustat dosing in Gaucher disease |
| JAK2 | Janus kinase 2, upstream of STAT3 | Inhibition by WP1066 reduces UGCG activity |
| STAT3 | Signal transducer and activator of transcription 3 | WP1066 inhibits JAK/STAT3, affecting UGCG |
| AHR | Aryl hydrocarbon receptor | Activation upregulates UGCG in epidermis |
| RAB32 | Small GTPase involved in ER-mitochondria communication | Mediates UGCG-dependent venetoclax resistance in AML |
| BCL2 | Anti-apoptotic protein | Venetoclax target; UGCG targeting sensitizes AML cells |
| CD8A | CD8 alpha chain, T cell co-receptor | Glucose-dependent glycosphingolipid biosynthesis fuels CD8+ T cell function |
| KRT10 | Keratin 10, differentiation marker | Correlates with UGCG induction in keratinocytes |
| KRT14 | Keratin 14, basal keratinocyte marker | UGCG activity changes during differentiation |
| UDP-glucose | Substrate for UGCG | Donor of glucose in the reaction |
| Ceramide | Substrate for UGCG | Acceptor of glucose; pro-apoptotic lipid |
| Glucosylceramide | Product of UGCG | Precursor for glycosphingolipids; biomarker |
| Lactosylceramide | Downstream product of glucosylceramide | Involved in cell signaling and cancer |
| GM3 | Ganglioside derived from lactosylceramide | Modulates immune cell function |
| Venetoclax | BCL2 inhibitor | Combined with UGCG targeting in AML |
| Eliglustat | UGCG inhibitor | Approved for Gaucher disease type 1 |
How Is ceramide glucosyltransferase activity Regulated?
Ceramide glucosyltransferase activity is regulated at multiple levels. Transcriptional upregulation of UGCG occurs via the aryl hydrocarbon receptor (AhR) in epidermal keratinocytes, linking environmental stimuli to glycosphingolipid synthesis. The JAK/STAT3 pathway inhibitor WP1066 directly inhibits UGCG activity, suggesting post-translational or direct enzymatic regulation. Additionally, UGCG activity is induced during keratinocyte differentiation, indicating developmental control. In cancer, UGCG expression can be elevated, contributing to chemoresistance, and its activity is modulated by cellular metabolic state, such as glucose availability.
ceramide glucosyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| UGCG | AML resistance to venetoclax | UGCG knockout AML cell lines, xenograft models |
| UGCG | Venous malformation | Endothelial cell-specific UGCG knockout or overexpression |
| UGCG | Gaucher disease | UGCG inhibition in patient-derived fibroblasts |
| UGCG | Skin barrier dysfunction | Keratinocyte-specific UGCG knockout mice |
| UGCG | CD8+ T cell-mediated tumor control | UGCG conditional knockout in T cells |
Cancer and Chemoresistance
UGCG is overexpressed in several cancers, including acute myeloid leukemia (AML), where it promotes resistance to the BCL2 inhibitor venetoclax. Targeting UGCG sensitizes AML cells to venetoclax through RAB32-mediated endoplasmic reticulum-mitochondria communication. In CD8+ T cells, glucose-dependent glycosphingolipid biosynthesis, which requires UGCG, is essential for tumor control, highlighting a role in immune evasion.
Venous Malformation
UGCG has been implicated in venous malformations, where its activity contributes to aberrant vascular development. Studies suggest that UGCG may influence endothelial cell behavior and vessel formation.
Skin Disorders and Barrier Function
In the epidermis, UGCG is upregulated by AhR activation and during keratinocyte differentiation, affecting skin barrier function. Dysregulation may contribute to inflammatory skin diseases.
Gaucher Disease and Lysosomal Storage Disorders
UGCG is the enzyme that synthesizes glucosylceramide, the substrate that accumulates in Gaucher disease due to deficient glucocerebrosidase. Inhibiting UGCG with eliglustat reduces glucosylceramide production and is a therapeutic strategy for Gaucher disease type 1.
From ceramide glucosyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of UGCG loss on glycosphingolipid levels? | UGCG knockout cell lines (e.g., HEK293, HeLa) |
| How does UGCG inhibition affect AML sensitivity to venetoclax? | UGCG knockout or inhibitor-treated AML cell lines |
| Does UGCG point mutation alter enzyme activity? | CRISPR knock-in of catalytic mutants (e.g., in UGCG active site) |
| How does UGCG overexpression affect T cell function? | UGCG overexpression in primary CD8+ T cells |
| Can we track UGCG localization in live cells? | Knock-in of fluorescent tag (e.g., GFP) at UGCG locus |
| What is the role of UGCG in venous malformation? | Endothelial-specific UGCG knockout mouse models |
How to Study the ceramide glucosyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| UGCG activity assay | Enzymatic transfer of glucose to ceramide | Measuring UGCG activity in cell lysates |
| CRISPR knockout | Loss of UGCG function | Studying effects on glycosphingolipids and cell viability |
| CRISPR knock-in | Introduction of point mutations | Dissecting catalytic residues or regulatory sites |
| Lipidomics (LC-MS) | Glycosphingolipid profiles | Quantifying glucosylceramide and downstream lipids |
| Immunofluorescence | Protein localization | Visualizing UGCG in Golgi |
| Western blot | Protein expression levels | Assessing UGCG upregulation |
| qRT-PCR | mRNA expression | Measuring UGCG transcriptional changes |
| Flow cytometry | Cell surface glycosphingolipids | Analyzing CD8+ T cell function |
Enzymatic Activity Assays
Ceramide glucosyltransferase activity can be measured using sensitive methods with deuterated glucosylceramide as an acceptor substrate, allowing precise quantification in biological samples. This assay is essential for determining the kinetic properties and inhibitor efficacy.
CRISPR-Cas9 Knockout and Knock-in
CRISPR-Cas9 can generate UGCG knockout cell lines to study loss of function, or knock-in of point mutations to dissect catalytic residues. These models help establish causality between UGCG activity and cellular phenotypes.
Lipidomics and Mass Spectrometry
Mass spectrometry-based lipidomics enables comprehensive analysis of glycosphingolipids, including glucosylceramide and its downstream products, in cells and tissues. This method is used to assess changes in UGCG activity.
Immunofluorescence and Imaging
Immunofluorescence microscopy can visualize UGCG localization in the Golgi apparatus and track glucosylceramide distribution. Live-cell imaging with tagged UGCG provides dynamic insights.
How CRISPR Can Be Used to Study GO:0008120 ceramide glucosyltransferase activity
Knockout
CRISPR-Cas9 knockout of UGCG eliminates ceramide glucosyltransferase activity, leading to reduced glucosylceramide and altered glycosphingolipid profiles. This model is used to study the role of UGCG in cancer, immune function, and development.
Point Mutation
Point mutations in UGCG can be introduced via CRISPR to dissect the catalytic mechanism or identify residues critical for substrate binding. For example, mutating the putative catalytic domain can abolish enzyme activity.
Knock-in
Knock-in of tags (e.g., GFP) or disease-associated mutations allows tracking of UGCG localization and function in live cells. This approach is valuable for studying UGCG trafficking and interaction partners.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of UGCG can elevate enzyme levels, mimicking pathological upregulation in cancer. This model helps investigate the consequences of increased glycosphingolipid synthesis.
How EDITGENE Supports ceramide glucosyltransferase activity Research
Researchers studying ceramide glucosyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in glycosphingolipid metabolism, disease progression, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for ceramide glucosyltransferase activity research.
Frequently Asked Questions About ceramide glucosyltransferase activity
What is ceramide glucosyltransferase activity?
Ceramide glucosyltransferase activity (GO:0008120) is the enzyme activity that transfers glucose from UDP-glucose to ceramide, forming glucosylceramide, the first step in glycosphingolipid synthesis.
What genes are involved in ceramide glucosyltransferase activity?
The primary gene is UGCG, which encodes the enzyme. Other genes such as AHR, JAK2, and STAT3 regulate its expression or activity.
What is the function of UGCG?
UGCG catalyzes the synthesis of glucosylceramide, a precursor for complex glycosphingolipids that are essential for cell signaling, membrane structure, and immune function.
How is ceramide glucosyltransferase activity measured?
It can be measured using a sensitive assay with deuterated glucosylceramide as an acceptor substrate, often coupled with mass spectrometry.
What diseases are associated with UGCG?
UGCG is implicated in cancer (e.g., AML), Gaucher disease, venous malformations, and skin disorders.
What inhibitors target ceramide glucosyltransferase?
Eliglustat is a clinically approved UGCG inhibitor for Gaucher disease. WP1066 also inhibits UGCG activity.
How does UGCG affect cancer treatment?
UGCG overexpression can confer resistance to chemotherapy; targeting UGCG sensitizes AML cells to venetoclax.
What is the role of UGCG in T cells?
Glucose-dependent glycosphingolipid biosynthesis via UGCG is required for CD8+ T cell function and tumor control.
Can CRISPR be used to study UGCG?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect UGCG function in health and disease.
Where is UGCG located in the cell?
UGCG is a Golgi-resident enzyme that catalyzes glucosylceramide synthesis on the cytosolic face of the Golgi membrane.
Conclusion
Ceramide glucosyltransferase activity (GO:0008120) is a fundamental enzymatic function that governs the entry of ceramide into glycosphingolipid biosynthesis. Its product, glucosylceramide, is a key precursor for numerous bioactive lipids that regulate cell growth, differentiation, and immune responses. Dysregulation of UGCG is linked to cancer, Gaucher disease, and vascular anomalies, making it a compelling therapeutic target. Advances in CRISPR-based models and sensitive activity assays continue to illuminate its mechanistic roles and potential for clinical intervention.
References
- 1. Longo J et al.. 2025. Glucose-dependent glycosphingolipid biosynthesis fuels CD8(+) T cell function and tumor control.. Cell Metab 37(9):1890-1906.e11 PMID: 40769148
- 2. Cas MD et al.. 2023. A sensitive method for determining UDP-glucose: ceramide glucosyltransferase (UGCG) activity in biological samples using deuterated glucosylceramide as acceptor substrate.. Glycobiology 33(2):88-94 PMID: 36504340
- 3. Sutter CH et al.. 2023. Ligand Activation of the Aryl Hydrocarbon Receptor Upregulates Epidermal Uridine Diphosphate Glucose Ceramide Glucosyltransferase and Glucosylceramides.. J Invest Dermatol 143(10):1964-1972.e4 PMID: 37004877
- 4. Chen S et al.. 2023. Role of UDP-glucose ceramide glucosyltransferase in venous malformation.. Front Cell Dev Biol 11:1178045 PMID: 37274734
- 5. Tsurumaki H et al.. 2017. WP1066, a small molecule inhibitor of the JAK/STAT3 pathway, inhibits ceramide glucosyltransferase activity.. Biochem Biophys Res Commun 491(2):265-270 PMID: 28739255
- 6. Sando GN et al.. 1996. Induction of ceramide glucosyltransferase activity in cultured human keratinocytes. Correlation with culture differentiation.. J Biol Chem 271(36):22044-51 PMID: 8703011
- 7. Pratt VM et al.. 2012. Eliglustat Therapy and CYP2D6 Genotype.. PMID: 33351401
- 8. Sun X et al.. 2026. Targeting UGCG sensitizes AML cells to venetoclax through RAB32-mediated endoplasmic reticulum-mitochondria communication.. Cell Rep 45(3):117021 PMID: 41734065
